Identity
Other names: TBX3-ISO, UMS, XHL HGNC (Hugo): TBX3 Location: 12q24.1 Note TBX3 is a member of the T-box transcription factor family, characterised by a conserved DNA-binding domain known as the T-box (Kispert and Herrmann, 1993; Bollag et al., 1994; Agulnik et al., 1996; reviewed in Papaioannou, 2001) . TBX3 belongs to the Tbx2 (also known as the Tbx2/3/4/5) subfamily, which includes the closely related genes Tbx2, Tbx3, Tbx4 and Tbx5 (Showell et al., 2004; Naiche et al., 2005) . Tbx3 plays critical roles in the development of several organs such as the heart, limb and mammary gland (Davenport et al., 2003; Hoogaars et al., 2007) . TBX3 is overexpressed in a range of cancers including breast, pancreatic and melanoma and has been directly implicated in tumourigenesis (Mahlamaki et al., 2002; Fan et al., 2004; Hoek et al., 2004) . It has been reported to promote evasion of apoptosis, migration, invasion and tumour forming ability (Brummelkamp et al., 2002; Ito et al., 2005; Renard et al., 2007; Peres et al., 2010) .
DNA/RNA
Note Tbx2 and Tbx3 both belong to the Tbx2 subfamily of T-box factors (Agulnik et al., 1996) . Phylogenetic analysis suggests that this subfamily originated from a single ancestral gene which was duplicated by unequal crossing over to form a two-gene cluster (Tbx2/3 and Tbx4/5) and at some point in the vertebrate lineage, duplicated again to form four separate genes with Tbx2 and Tbx4 linked on chromosome 11, and Tbx3 and Tbx5 on chromosome 5 (chromosomes 17q23 and 12q24 respectively in humans; Figure 1A ) (Campbell et al., 1995; Agulnik et al., 1996; Bamshad et al., 1997) . Due to the original duplication event, Tbx2 and Tbx3 form a closely related gene pair while Tbx4 and Tbx5 are more closely related to each other (Agulnik et al., 1996) .
Description
The human TBX3 gene is found on the reverse strand of chromosome 12 and spans 13.9 kb.
Transcription
Four TBX3 transcripts have been identified but only two encode for full length functional proteins viz TBX3 and TBX3 + 2a ( Figure 1B ). The TBX3 mRNA is 4.7 kb and contains 7 exons encoding a protein of 723 amino acids. Alternative splicing of the intronic region between exons 2 and 3 gives rise to the TBX3 + 2a transcript which contains an extra 60 bp sequence designated exon 2a leading to the production of a 743 amino acid protein (Bamshad et al., 1999) . TBX3 and TBX3 + 2a isoforms are widely expressed in mouse and human tissues with TBX3 generally observed to be the dominant isoform and the ratio between the two being both tissue and species dependent (Fan et al., 2004) . 
Protein

Note
The TBX3 + 2a transcript yields a protein with an extra 20 amino acids in the middle of the T-box DNA binding domain, giving rise to speculation that it may affect the DNA-binding ability of the protein (Bamshad et al., 1999) . While the work of Fan et al. (2004) has provided evidence supporting this hypothesis, subsequent studies have shown no functional difference between the TBX3 and TBX3 + 2a proteins (Hoogaars et al., 2008; Rodriguez et al., 2008) .
Description
The T-box DNA binding domain is found in the Nterminal half of the TBX3 protein extending from amino acids 104 -285 and in the TBX3 + 2a isoform, the additional 20 amino acids are inserted into the middle of the T-box at position 219 (Figure 2 ). TBX3 has two repression domains, one in the N-terminus and one in the C-terminus of the protein, as well as a putative activation domain located in the C-terminal end of the protein (Figure 2) (Carlson et al., 2001 ).
Expression
In humans, TBX3 is expressed in a number of organs, including foetal heart, liver, spleen, lung and kidney, and in adult prostate, lung, placenta, ovary, spleen, heart, kidney, testis, small intestine, adrenal gland, thyroid, breast, bladder, uterus, liver and salivary gland (Bamshad et al., 1999) .
Localisation
The TBX3 protein is predominantly nuclear.
Function
TBX3 has been described to function as a transcriptional repressor and to date was shown to directly repress p14, p21, E-cadherin and phosphatase and TENsin homolog (PTEN) Hoogaars et al., 2008; Rodriguez et al., 2008; Burgucu et al., 2012) . While in vitro assays have suggested that TBX3 is capable of transcriptional activation, it has not yet been shown to activate any physiologically relevant target genes.
Homology
Human TBX3 shares 98% amino acid identity with mouse Tbx3 and homologs have been identified in mammals, reptiles, fish and amphibians, as well as invertebrates such as tunicates (Bamshad et al., 1997) .
Mutations
Germinal
Mutations in human TBX3 have been linked with ulnar-mammary syndrome and those described to date include frame shift, premature termination and missense mutations (Bamshad et al., 1997; Bamshad et al., 1999) .
Implicated in
Ulnar-mammary syndrome
Note
Results from congenital mutations in a single copy of the human TBX3 gene. Disease Characterised by posterior limb abnormalities, such as malformed ulna and posterior digits, hypoplasia and/or dysfunction of the mammary and apocrine glands, absent axillary hair, abnormal dentition, delayed puberty in males and genital anomalies (Bamshad et al., 1996; Bamshad et al., 1997) .
Breast cancer
Note Breast cancer lines screened by real time PCR analysis displayed increased expression of TBX3 in 15 of 28 cell lines tested (Fan et al., 2004) . When TBX3 expression was examined by immunohistochemistry in breast tumour tissues, the results showed that levels of TBX3 protein were higher in tumour tissue compared to adjacent normal tissue, with increased cytoplasmic localisation.
Pancreatic cancer
Note
Microarray analyses comparing non-metastatic and metastatic pancreatic endocrine neoplasms revealed that TBX3 expression is upregulated in the latter tumour type (Hansel et al., 2004) .
Ovarian cancer
Note Using 2D gel electrophoresis and matrix-assisted laser desorption/ionization (MALDI) time of flight (TOF) mass spectrometry, a truncated form of TBX3 was detected in blood plasma from ovarian cancer patients (Lomnytska et al., 2006) .
Liver cancer
Note
Increased TBX3 expression was shown to correlate with a mutant active form of β-catenin in both human and mouse hepatocellular carcinomas (HCCs) and human hepatoblastomas. Renard et al. (2007) demonstrated TBX3 to be involved in β-catenin's activation of cell proliferation in the human hepatoma cell line HepG2. Using in vitro assays they showed that expression of mutant β-catenin upregulated TBX3 expression and that this was due to direct binding of active β-catenin together with its co-activator T-cell factor (Tcf) to a Tcf-binding element in the TBX3 promoter (Renard et al., 2007) .
Glioblastoma
Note Genome-wide DNA methylation profiling of 55 glioblastoma tissue samples compared to nonneoplastic brains revealed that methylation of TBX3 correlated with decreased overall survival, identifying it as a potential independent prognostic marker (Etcheverry et al., 2010) .
Gastric cancer
Note Genome-wide screening identified TBX3 to be epigenetically silenced in the gastric cancer cell line AGS and the TBX3 gene was shown to be methylated in 7 out of 10 primary gastric cancers (Yamashita et al., 2006) .
Uterine cervical cancer
Note TBX3 expression was shown to be downregulated in microarray analyses comparing lymph node positive to lymph node negative cervical tumours. A significant correlation was observed between low TBX3 expression and the metastatic phenotype. In addition, multivariate analysis identified TBX3 as a potential independent prognostic marker for this cancer (Lyng et al., 2006) .
Melanoma
Note
In 2004, Hoek et al. showed that compared to normal melanocytes TBX3 expression was upregulated in at least 4 of 6 melanoma cell lines tested and later demonstrated increased TBX3 protein levels in 6 out of 12 melanoma cell lines. Furthermore, TBX3 was shown to contribute to melanoma formation, migration and invasion by a process involving its ability to repress the cell adhesion molecule E-cadherin Peres et al., 2010) .
Head and neck squamous cell cancer
Note TBX3 is upregulated in head and neck squamous cell carcinoma (HNSCC) cell lines and tissues (Humtsoe et al., 2011; Burgucu et al., 2012) . The study by Humtsoe et al. shows that TBX3 expression is specifically upregulated in HNSCC cells which display characteristics of epithelial to mesenchymal transition (EMT). Interestingly, however they show that TBX3 promotes cell survival and to a lesser extent, cell invasion in these cells (Humtsoe et al., 2011) . This is consistent with the results of Burgucu et al. (2012) which demonstrate that TBX3 represses the tumour suppressor, phosphatase and TENsin homolog (PTEN).
